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Severe sepsis and septic shock are still deadly conditions urging to develop novel therapies. A better understanding of the complex
modifications of the immune system of septic patients is needed for the development of innovative immunointerventions. Natural
killer (NK) cells are characterized as CD3−NKp46+CD56+ cells that can be cytotoxic and/or produce high amounts of cytokines
such as IFN-γ. NK cells are also engaged in crosstalks with other immune cells, such as dendritic cells, macrophages, and
neutrophils. During the early stage of septic shock, NK cells may play a key role in the promotion of the systemic inflammation,
as suggested in mice models. Alternatively, at a later stage, NK cells-acquired dysfunction could favor nosocomial infections and
mortality. Standardized biological tools defining patients’ NK cell status during the diﬀerent stages of sepsis are mandatory to
guide potential immuno-interventions. Herein, we review the potential role of NK cells during severe sepsis and septic shock.
1. Introduction
Sepsis is the clinical presentation of a “systemic inflammatory
response syndrome” (SIRS) to a severe infection. Most clini-
cal and basic-science research on the immune consequences
of severe sepsis conducted during the last decades has focused
on the roles of macrophages, neutrophils and conventional T
lymphocytes [1]. During recent years, however, it has become
increasingly clear that subsets of innate immune cells, such
as natural killer (NK) cells, are involved in both protective
immunity and immunopathology.
Herein, we review the potential role of NK cells during
the diﬀerent stages of severe sepsis and septic shock.
2. Severe Sepsis: Urgent Needs for
“Immunological” Solutions
The most threatening infections are referred to as severe
sepsis and septic shock [1]. These severe forms of infec-
tion, mainly of bacterial origin, represent a major health-
care problem, accounting for thousands of deaths every
year worldwide, with more than 200,000 deaths per year
just in the United States [2]. Sepsis, severe sepsis, and
septic shock are viewed as a continuum that results in
increasing mortality (cf. Figure 1) and shares consensual
clinical criteria [3]. Mortality is up to 50% in septic
shock, and the incidence of sepsis is projected to increase
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Figure 1: Continuum from infection to septic shock: the initial
response to pathogen is a systemic response, with release of in-
flammatory mediators and activation of the coagulation cascade,
resulting in imbalance between oxygen delivery and oxygen con-
sumption. Ultimately, tissue hypoxia develops and may lead to
multiple organ dysfunction and irreversible shock.
significantly during next years with higher rates of mortality
due to more advanced age and/or associated comorbidities
(cancer, diabetes, etc.). During the last decades, physicians
have made significant progress in the early implementation
of symptomatic care through adequate fluid resuscitation,
antibiotherapy, and specific organ-support techniques, such
as mechanical ventilation and renal-replacement therapy.
Unfortunately, these therapeutic strategies have failed to
suﬃciently reduce mortality in severely septic patients [4,
5]. Moreover, physicians are increasingly concerned about
increasing microbial resistance to antibiotics and the slow
development of new antimicrobial agents [6]. Thus, there is
an urgent need to develop eﬃcacious therapies to treat this
deadly disease.
Future therapies may emerge from a better understand-
ing of the physiopathology of sepsis [7]. Sepsis, also referred
to as SIRS of septic origin, was originally viewed as an
exacerbated inflammatory response and a “cytokine storm.”
However, most trials that used inhibitors of proinflammatory
cytokines or inhibitors of proinflammatory mediators failed
to improve patients’ outcomes, providing the best proof of
the incomplete understanding of its pathogenesis [8, 9]. One
of the reasons for the lack of eﬃcacy of anti-inflammatory
strategies in patients with sepsis may be because the syn-
drome changes over time [10].
In its early stages, sepsis is characterized by an increase
in inflammatory mediators, but as sepsis persists, there is
a shift towards an anti-inflammatory immunosuppressive
state. Indeed, a common feature of these patients is the
alteration of their immune status, referred to as “com-
pensatory anti-inflammatory response syndrome” (CARS),
which is thought to render patients more susceptible to
nosocomial infections. It seems that immune dysfunctions
that are supposed to play a role in mortality vary between
patients who succumb within the first hour after sepsis and
those who survive the first critical hours (>80%) but then
die later from sepsis-induced multiorgan dysfunction and/or
secondary nosocomial infections. It has only been recently
that eﬀorts to understand the eﬀect of the inflammatory
process on the immune status during septic shock have fully
integrated the considerable derangements of both the innate
and adaptive immune systems and have better identified the
contribution of multiple cellular actors [1, 7].
3. NK Cells: Early Soldiers with
Multiple Functions
NK cells are lymphocytes that are classically referred to as
part of the innate immunity. NK cells were first described for
their ability to kill leukemic cells without prior specific sen-
sitization [11]. They represent a small proportion (4–15%)
of blood lymphocytes and do not express a specific receptor
for antigens dependent upon RAG-mediated rearrangements
[12]. NK cell function is regulated by a multiplicity of acti-
vating and inhibitory receptors. Their natural cytotoxicity is
largely under the control of natural cytotoxicity receptors,
and their antibody-dependent cytotoxicity is linked to the
engagement of CD16/FCγ RIIIa [13]. Human NK cells are
characterized as CD3− NKp46+CD56+ cells [14]. In humans,
blood NK cells can be divided into two major subtypes:
CD56bright and CD56dim, corresponding to sequential steps
of diﬀerentiation [15]. The former subtype represents
about 10% of circulating NK cells. These cells express
low levels of CD16 and perforin, produce high amounts
of cytokines (e.g., interferon gamma or IFN-γ, TNF-α,
and granulocyte-macrophage colony-stimulating factor) in
response to cytokines such as interleukin (IL)-12 and IL-18,
and represent the major fraction of NK cells in lymph nodes.
CD56dim NK cells express high levels of CD16, perforin,
and killer Ig-like receptors (KIRs). KIRs include inhibitory
receptors that recognize MHC class I molecules and dampen
NK cell activation. CD56dim NK cells are cytotoxic by granule
polarization and exocytosis of various proteins including
perforin and granzymes, which mediate target-cell killing
and are also cytokine producers.
Several lines of evidence suggest that NK cells might
be involved in key functions during sepsis. NK cells have a
major role in defense against viral infections, in particular
herpesvirus [16], influenza viruses [17], or hantavirus [18],
by direct cytotoxicity against virus-infected cells and by
the early production of cytokines that can control viral
replication, such as IFN-γ. NK cells also participate in
responses to other types of infections, including those
caused by intracellular bacteria, pyogenic bacteria, fungi,
and protozoa [19, 20]. As the early and main producers
of IFN-γ during sepsis, these cells are equipped with many
innate sensors for damage-associated molecular-pattern
molecules (DAMPS) and pathogen-associated molecular-
pattern molecules (PAMPS) [21]. In addition, if NK cells
are found within the blood stream, they are also abundant
in some tissues, such as the lungs [22, 23], an organ par-
ticularly prone to dysfunction in Intensive Care Unit (ICU)
patients. NK cells are also engaged in crosstalks with other
immune cells, such as dendritic cells (DCs) [24], monocytes,
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macrophages [25, 26], and neutrophils [27], which besides
being fundamental for NK cell activation in response to
most pathogens (by direct contact or cytokine secretion) also
participate in the development of the subsequent immune
response (Figures 2(A) and 2(B)).
4. NK Cells and Severe Sepsis: Lessons and
Limits fromMurineModels
Most of the current knowledge about the role of NK cells
during severe sepsis comes from mouse models. Although
NK cell-deficient mice are not reported to present with
detectable abnormalities at steady state, all data converge
on a detrimental role for NK cells during sepsis. In mice,
a challenge with high doses of lipopolysaccharide (LPS)
results in a syndrome resembling septic shock in humans,
and depletion of NK cells oﬀers protection against LPS-
induced shock [28, 29]. Depletion of NK cells by systemic
administration of polyclonal antiasialo GM1 or monoclonal
anti-NK1.1 antibodies, before the induction of the general-
ized Schwartzman reaction, leads to a dramatic reduction
in mortality and significantly lowers cytokine levels (IFN-
γ and TNF-α) following a systemic injection of LPS [28].
The same protective eﬀect against cytokine-induced shock
(by administrating IL-12 in combination with IL-2 or IL-15)
was observed in mice that underwent depletion of NK cells
with antiasialo GM1 antibodies [30].
In addition, there is now increasing evidence of detri-
mental roles for NK cells in diﬀerent models of bacterial
infections. Depletion of NK cells in SCID mice infected
intranasally with Streptococcus pneumoniae resulted in signif-
icantly lower bacteremia and inflammatory cytokine produc-
tion within the lung airways and lung tissue [31]. Improved
survival was also observed with NK-cell-depleted mice in a
model of septic shock with Streptococcus pneumoniae [32].
In a model of cecal ligation and puncture (CLP), mice
treated with anti-asialo-GM1 were protected against CLP-
induced mortality compared to IgG-treated controls [32].
During CLP-induced shock, NK cells migrated from blood
and spleen to the inflamed peritoneal cavity where they
amplified the proinflammatory activities of the myeloid
cell populations [33]. NK cells were also involved in the
high levels of inflammatory cytokines, lung pathology, and
mortality that occur during Escherichia coli peritonitis, as all
these parameters were reduced by NK depletion [34].
Altogether, these results suggest that NK cells can pro-
mote the inflammatory process occurring during sepsis
in vivo, possibly via interactions with macrophages [35,
36], organ infiltration and damage, and the secretion of
proinflammatory cytokines, providing a rationale basis to
explain how NK-cell depletion increases survival in exper-
imental sepsis. In opposition to this role of amplification
of inflammation, recent data show that very early during
the course of systemic infections induced by Toxoplasma
gondii, Listeria monocytogenes, and Yersinia pestis, IL-12
secreted by DC induces NK cells to produce the broadly
immunosuppressive cytokine IL-10, which, in turn, inhibits
IL-12 secretion by DC, unveiling an immunosuppressive
“regulator” function of NK cells [37]. If documented in
humans, NK cells might then contribute to the necessary
transition from SIRS to CARS (cf. Figure 2).
Mice are the most commonly used animal models in
biomedical research, and rodent studies are an important
part of the preclinical studies that determine progression
to clinical studies in humans during drug development.
However, there are numerous concerns about extrapolation
from what is known about mouse to human NK-cell biology
during severe sepsis, thus limiting the clinical relevance of
the mouse models described above. Because there was no
genetic model where NK cells could be selectively deleted, in
vivo NK-cell depletion has so far relied on anti-asialo-GM1-
or anti-NK1.1-depleting antibodies. Although a depletion of
NK cells can be obtained with both antibodies, the selectivity
of the depletion depends upon the quantities of antibodies,
blurring the interpretation of the results obtained using these
methods. More recently, transgenic mice that lack NK cells,
but have a normal T/NKT-cell compartment, have been
reported [38], but the cause of selective NK-cell ablation
in these mice is linked to the expression of the ubiquitous
transcription factor, ATF2, which raises the possibility of
other defects in the immune system [39]. Moreover, the
basic leucine-zipper transcription factor E4BP4 (also called
NFIL3) has been proven essential for the generation of
the NK-cell lineage and E4BP4-deficient mice specifically
lack NK cells [40]. However, E4BP4-deficient mice were
also shown to undergo impaired B-cell intrinsic IgE class
switching [41]. Finally, taking advantage of the identification
of a functional NKp46 promoter, a mouse model of condi-
tional NK cell ablation based on the diphtheria toxin (DT)
receptor/DT-based system has been generated [42]. Because
DT injection leads to a complete and selective ablation of NK
cells in these mice, this model provides a precious tool to
explore the role of NK cells in many pathological conditions,
including sepsis.
However, even with the availability of selective NK-cell
deficient models [42] or of humanized mouse models [43],
a constant problem with the murine approach to study
sepsis is that rodents are highly resilient to most models
of induced inflammation as compared to humans and that
results depend on the strain and models of sepsis used (from
LPS injection to cecal ligation and puncture). Also, because
the supportive care used in humans is not easily transposed
into mice [44], these models of septic challenge are not fully
relevant to address the particular situation of ICU patients
who survive the most severe sepsis and then come to the
“immunosuppressive” CARS stage, which is responsible for
most deaths.
5. A Role for NK Cells in Human SIRS?
By analogy with the possible use of the NK cell-deficient
mouse model, we could consider the study of patients with
NK cell-selective deficiency to address the role of NK cells
in severe human sepsis. A number of isolated deficiencies
of NK cells in humans have been described, but most
are complex immunodeficiencies associated with absent
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Figure 2: (A) NK cells initiate a local inflammatory response to pathogens. (B) During SIRS, NK cells amplify the inflammatory response
to the spread of the pathogen, which can lead to organ dysfunction. (C) Deficient NK cell cytotoxicity may favor macrophage activation
syndrome. (D) During CARS, NK cell global dysfunction may favor nosocomial infections. Note: SIRS and CARS have been separated in
time to ease understanding of the figure, but the diﬀerent stages (B–D) can occur simultaneously. Also, most data shown here are from
mouse models and should be further confirmed in septic patients.
or functionally deficient NK cells [45]. Few reports have
described patients with isolated NK-cell abnormalities where
the main susceptibility is to severe infection with herpesvirus
[46]. The paucity of nonambiguous cases of NK-selective
deficiencies in humans has hampered the identification of
nonredundant NK-cell function. Also, as some SCID-X1
patients with no NK cell reconstitution after allogenic bone-
marrow transplantation or gene therapy do not experience
severe infections, it has been suggested that NK cells might
have redundant anti-infectious functions in humans [47].
However, NK cells have been reported to be key in controlling
severe cytomegalovirus (CMV) infection in some patients
[48]. In septic shock, as fatality can precede adaptive
responses, and in the context of massive and sometimes
persistent apoptosis-induced T- and B-cell lymphopenia
[49], NK cells may play a crucial and nonredundant role.
Our knowledge of NK cells in severe human sepsis and
septic shock could be derived from analyses of NK cells taken
directly from patients during the diﬀerent clinical stages of
the disease. However, available data from patients in ICU
are scarce and heterogeneous and do not always include
evaluation of cell function. Because of all these limitations,
these results appear as contradictory. Yet, in patients with
severe Gram-negative sepsis, an increased percentage of
blood NK cells has been reported, as an improved survival in
the patients with high NK counts [50]. Of importance, these
patients did not experience septic shock nor were admitted
into the ICU. Unfortunately, NK cell eﬀector functions were
not monitored in this study. A previous report had observed
that NK-cell counts were higher among patients with sepsis
of Gram-positive origin than among patients with Gram-
negative sepsis [51].
In contrast, previous studies on patients with SIRS [52]
and septic shock [53] had reported reduced numbers of
NK cells and impaired NK cell in vitro cytotoxicity against
K562 tumor cells. However, when NK cell cytotoxicity in
patients with severe sepsis or septic shock was assessed in
vivo by measuring circulating granzyme A and B levels [54],
higher cytotoxicity was found in 50% of septic patients,
and these patients had a higher mortality and worse organ
function. Altogether, as suggested by a recent prospective
study conducted in more than 500 patients with early sepsis,
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the discrepancies concerning the number and/or function of
circulating NK cells are probably due to the heterogeneity of
patients in terms of either severity (severe sepsis and/or septic
shock) or involvement of pathogens (Gram-negative versus-
positive bacteria) [55].
Also, because septic shock is rapidly associated with a
dramatic decrease in circulating lymphocytes, the timing
of NK-cell analysis might be of particular importance. It
is reported that, from their admission into an ICU, the
numbers of all lymphocyte subpopulations (including NK
cells) of 21 septic-shock patients were diminished, and these
alterations remained stable during the first 48 h [56], while
no data are available after this short time.
Another caveat in these human studies is that NK cell
testing has been obviously limited to peripheral blood. AsNK
cells can migrate out of the blood into the inflamed tissues,
the interpretation of the analysis may be diﬃcult. Indeed,
the status of NK cells within tissues might be quite diﬀerent
[57, 58]. Only one study has addressed NK cells at a tissular
level in human septic shock. In this paper, Hotchkiss et
al. described a profound and progressive, apoptosis-induced
loss of B and CD4+ T cells in the spleen and gut-associated
lymphoid tissue of adults who had died of sepsis [49]. In
contrast, a trend towards an increase of splenic NK cells
was observed in septic patients. This result failed to reach
statistical significance, most likely as the consequence of the
small number of patients.
Thus, with cautious interpretation, due to the mentioned
heterogeneity in studied patients and the complete absence of
data concerning NK cell cytokine secretion, human studies
do not exclude a detrimental role for NK cells in the early
stage of septic shock (Figure 1) that was observed in mouse
models [49, 54].
6. A Role for NK Cells in Human CARS?
As the vast majority of patients with sepsis survive the initial
insult, we should consider not only the initial excessive sys-
temic inflammatory reaction, but also the following sepsis-
induced immunosuppressive period and its consequences.
During severe sepsis, some patients can develop sec-
ondary hemophagocytic lymphohistiocytic (HLH) syn-
drome, also termed macrophage activation syndrome
(MAS). For intensivists, the features of MAS mainly include
nonremitting fever, severe cytopenias, and organ dysfunc-
tions. MAS is characterized by uncontrolled macrophage
and Th1-lymphocyte stimulation, with elevated levels of
circulating INF-γ, TNF-α, IL-6, and IL-18 [59]. Many clues
to the role of NK cells in MAS have been recently discovered.
First, a marked decrease in NK cell numbers, as well as a
severe decrease in both natural cytotoxicity and ADCC, has
been reported in patients with secondary MAS [60]. Instead
of being just a consequence of MAS, this defect of NK cell
number and function could be part of the pathogenesis.
Indeed, the genetic forms of HLH are characterized by an
intrinsic defect of NK cell and T-cell cytotoxicity related
to the perforin/granzyme release pathway [61], and virally
infected perforin KOmice represent a relevant model ofMAS
[62]. Interactions between humanNK cells andmacrophages
are bidirectional and can result in activation of NK cells or in
the regulation of macrophage activity through the killing of
activated macrophages by NK cells [63]. Thus, even if NK
cells are early and massive sources of INF-γ, and contribute
to the initial excessive inflammatory response in severe sepsis,
a concomitant defect of their cytotoxic functions could
predispose a subset of these septic patients to develop MAS
because NK cell dysfunction may contribute to uncontrolled
Th1-lymphocyte and macrophage activation (Figure 2(C)).
Reduced NK cell numbers and functions, if persistent,
may also contribute to impaired host defenses during CARS
(Figure 2(D)). This “compensatory” inhibitory response,
which is primarily seen as a regulation for hyperinflamma-
tion, can then become deleterious as many immune func-
tions are compromised. These alterations may be directly
responsible for the worsening outcome, as they may play
a major role in the decreased resistance to nosocomial
infections in patients who have survived an initial resusci-
tation. In humans, this view is actually merely speculative
as up to now only a single study has been reported,
which includes an evaluation of NK cells in ICU patients
with septic shock that was not restricted to the very early
stage of shock [64]. In this study, NK cell cytotoxicity was
evaluated at diﬀerent time points from admission, and it
was suppressed to <10% in nearly all patients during the
complete observation period (up to 14 days). Interestingly,
ICU patients presenting with septic shock seem more prone
than others to develop reactivation of CMV [65]. These CMV
reactivations occur mainly at the late stage of sepsis although
the aﬀected patients seem to have suﬃcient CMV-specific
CD4+ or CD8+ T cells [64, 66]. These data suggest that
there might be a decrease in NK cell function that favors
the progression of the viral infection. Finally, ICU patients
with CMV reactivation (up to 30% of all ICU patients) may
developmore bacterial/fungal nosocomial infections because
of the immunosuppressive properties of CMV [65], but one
cannot exclude the possibility that NK cells also participate
in protective immunity against nosocomial pathogens [67].
7. NK Cells and Future Therapies for
Severe Human Sepsis: Perspectives
Most of the published data on human sepsis do not
examine both NK cell numbers and functions and, thus, have
incompletely assessed NK cell status. Nowadays, there are
rapid and relatively inexpensive methods to assess NK cell
functions directly at the patient bedside, using multipara-
metric functional flow cytometry [68]. Both quantitative and
qualitative evaluation of NK status now needs to be broadly
performed among ICU patients.
In addition, a single parameter will likely not be suﬃcient
to characterize the complexity of septic patients’ immuno-
logical status, which rapidly changes over time. Therefore,
the introduction of high-throughput technologies represents
an emerging solution for the global immunomonitoring
of sepsis. DNA microarrays and RNAseq allow genome-
wide assessment of changes in mRNA abundance. A first
transcriptomic approach could be restricted to NK-specific
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genes. Strikingly, less than a hundred genes might be
suﬃcient to define the human NK cell-specific signature
[69]. One should also look for NK cell-specific combinations
of more broadly expressed genes during the diﬀerent phases
of severe sepsis. This global functional approach has been
recently performed as a modular approach in diﬀerent
human pathological conditions [70, 71].
As for the potential development of any NK-based
immunointervention, new approaches should also allow to
better define the complex and dynamic actions of NK cells
during the diﬀerent phases of severe sepsis in humans. At
present, targeted NK cell therapies address hematopoietic
malignancies using diﬀerent strategies to enhance NK cell
functions and promote their antitumor action [72]. These
innovative protocols could be used in the “CARS” period
when ICU patients suﬀer from immunosuppression and
nosocomial infection. NK cells stimulation could be achieved
by manipulation of NK receptors (i.e., using anti-KIR-
specific antibodies that block inhibitory receptors) or by the
administration of cytokines as IL-15. The last option has
proved successful in murine model of sepsis and pneumonia,
where administration of IL-15 could prevent apoptosis,
increase the percentage of NK cells that produce IFN-γ,
and reverse immune dysfunction [73]. The restoration of
INF-γ secretion by NK cells that might be able to migrate
and deliver cytokine into the infected tissues at the right
time might be more eﬃcient than the direct parenteral
administration of INF-γ [74]. Alternatively, in the very early
phase of severe sepsis, monoclonal antibodies, targeting, for
example, NKp46, could be also designed to downregulate
or deplete NK cells and prevent the consequences of
uncontrolled inflammation due to their gamma interferon
secretion. NK cell depletion should be transient to avoid a
supplementary “immunodepression” due to persistent NK
depletion during CARS. Also, it might be diﬃcult to use it
early enough in patients initiating a septic shock out of the
hospital; but instead, inpatients, for example, presenting a
postsurgical sepsis, could be carefully screened and receive
immunointervention at the earliest phase of sepsis or even
at a presymptomatic phase of sepsis, if it can be robustly
diagnosed [75].
Translation to its clinical application must carefully take
into account the timing of administration of immunother-
apeutical agent. Thus, one of the first goals should be
first to achieve robust and standardized biological tools
that accurately define the patient’s immune status, so that
physicians can decide who can benefit, and when, from those
immunointerventions.
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